Abstract | BACKGROUND: METHODS: Patients in this 12-week, open-label study had biopsy-proven vulvar LSC. Inclusion criteria were patient-reported Visual Analog Scale for Pruritus Relief > or = 3 (VAS-PR, 0 cm = no itching to 10 cm = severe itching) and Investigator's Global Assessment > or = 2 ( IGA, 0 = no disease to 3 = severe disease). Safety was evaluated by adverse event reports and pimecrolimus blood level measurements. RESULTS: Twelve women aged 25-53 years were enrolled. The median pruritus score (VAS-PR) decreased from 6 (min. 4.9, max. 9.0) at baseline to 0 cm at week 4 (max. 4.2), week 8 (max. 3.1) and week 12 (max. 2.1). Seven patients reported complete resolution of pruritus by week 4. Median IGA decreased from 2.5 (min. 2, max. 3) at baseline to 0 (min. 0, max. 2) at week 12. Erythema, excoriation, and lichenification improved for all patients. Pimecrolimus blood concentration for all samples was below the limit of quantification, 0.3 ng/ml. No adverse events were reported. CONCLUSIONS: In this exploratory study, signs and symptoms of vulvar LSC improved for all women and pimecrolimus cream showed a favorable safety profile. Larger prospective studies are needed to further evaluate pimecrolimus for treatment of vulvar LSC.
|
Authors | Andrew T Goldstein, Anne Parneix-Spake, Calogera L McCormick, Lara J Burrows |
Journal | Gynecologic and obstetric investigation
(Gynecol Obstet Invest)
Vol. 64
Issue 4
Pg. 180-6
( 2007)
ISSN: 1423-002X [Electronic] Switzerland |
PMID | 17664878
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | 2007 S. Karger AG, Basel |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- pimecrolimus
- Tacrolimus
|
Topics |
- Administration, Cutaneous
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, blood, therapeutic use)
- Female
- Humans
- Middle Aged
- Neurodermatitis
(drug therapy, pathology)
- Severity of Illness Index
- Tacrolimus
(administration & dosage, analogs & derivatives, blood, therapeutic use)
- Treatment Outcome
- Vulvar Diseases
(drug therapy, pathology)
|